Lineage Cell Therapeutics, Inc. Accrued Liabilities, Current
Lineage Cell Therapeutics, Inc. (LCTX) had Accrued Liabilities, Current of $1.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $1.00M.
- 2026-03-31: Accrued Liabilities, Current $1.23M.
- 2025-12-31: Accrued Liabilities, Current $1.10M.
- 2025-09-30: Accrued Liabilities, Current $486.00K.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.23M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $1.10M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $486.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $793.00K 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $902.00K 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $1.20M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $384.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $414.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $991.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $1.10M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $349.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $581.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $404.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $3.83M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $5.00M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $4.50M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $4.34M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $22.09M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $1.54M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $802.00K 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $988.00K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $1.71M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $2.03M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $763.00K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $807.00K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $1.25M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $904.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $2.04M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $2.48M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $1.64M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $1.39M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $1.92M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $2.01M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $2.37M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $2.77M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $2.38M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $3.74M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $3.21M 10-K · filed 2018-03-15 | |
| 2016-09-30 | $3.51M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $3.55M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $5.22M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $5.02M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $4.73M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $3.14M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $3.09M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $3.13M 10-K · filed 2016-03-15 | $3.13M 10-K · filed 2015-03-11 |
| 2013-12-31 | $2.30M 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |